Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134116) titled 'A study of the efficacy and safety of anlotinib hydrochloride in combination with immune checkpoint inhibitors in the first/second line of advanced or unresectable cholangiocarcinoma and pancreatic cancer (CPC)' on Oct. 10.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Kaifeng Central Hospital
Condition:
Hepatic cholangiocarcinoma, bile duct cancer, gallbladder cancer, pancreatic cancer, ampullary cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2023-06-23
Target Sample Size: Observation group:30;
Countries of Recruitment:
China
To know mo...